Target

BCMA

Tumor necrosis factor receptor superfamily member 17

Also: TNFRSF17

213open trials
294trials in total
154publications
0researchers

Diseases

Multiple myeloma201 trials
Lupus (SLE)43 trials
Systemic sclerosis (scleroderma)28 trials
ANCA-associated vasculitis15 trials
Amyloidosis14 trials
Multiple sclerosis14 trials
Myasthenia gravis14 trials
IgA nephropathy8 trials
Neuromyelitis optica (NMOSD)8 trials
Rheumatoid arthritis7 trials
Sjögren's disease6 trials
Acute lymphoblastic leukaemia5 trials
Childhood cancers4 trials
Chronic kidney disease4 trials
CIDP (chronic inflammatory demyelinating polyneuropathy)4 trials
Ulcerative colitis3 trials
Acute myeloid leukemia2 trials
Crohn's disease2 trials
Diffuse large B-cell lymphoma2 trials
Pulmonary arterial hypertension2 trials

The last 24 months

New trials, publications, preprints and grants on this target, month by month.

TrialsPublicationsPreprintsGrants

Trial
Study of YKST02 in Adults With Relapsed or Refractory Multiple Myeloma
1 Dec 2027· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Universal CAR-T Cells Targeting Multiple Myeloma
30 Jun 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
1 Mar 2027· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
1 Feb 2027· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma
1 Feb 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
1 Jan 2027· PHASE3 · NOT_YET_RECRUITING· CTGOV
Trial
Multi-CAR T Cell Therapy in the Treatment of Multiple Myeloma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
31 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
1 Dec 2026· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
BCMA Polymorphisms in Patients With Multiple Myeloma
1 Nov 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
1 Nov 2026· PHASE1 · RECRUITING· CTGOV
Publication
Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.
1 Nov 2026· Hematological oncology· PUBMED
Trial
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
31 Oct 2026· PHASE3 · NOT_YET_RECRUITING· CTIS
Publication
Prognostic value of simultaneous [18F]FDG-PET/MRI in refractory multiple myeloma treated with anti-BCMA CAR T.
26 Oct 2026· HemaSphere· PUBMED
Publication
Concurrent administration of BCMA and GPRC5D CAR T cells for advanced multiple myeloma.
22 Oct 2026· Blood· PUBMED
Trial
A Study to Evaluate the Subcutaneous Belantamab (BCMAb) Formulation Versus Intravenous Belantamab in Participants With Multiple Myeloma While Treated With Standard of Care
16 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
15 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publication
Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations.
13 Oct 2026· Blood advances· PUBMED
Publication
Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis.
13 Oct 2026· Blood advances· PUBMED
Publication
Identification of B-cell maturation antigen (BCMA)-targeting peptides and selective drug delivery to multiple myeloma using peptide-targeted DM1 prodrug-loaded nanoparticles.
9 Oct 2026· Nanoscale advances· PUBMED
Publication
Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma.
7 Oct 2026· HemaSphere· PUBMED
Publication
BCMA-Targeted Immunotherapy in Early Relapsed/Refractory Multiple Myeloma: Mechanisms, Clinical Evidence, and Practical Management.
7 Oct 2026· European journal of haematology· PUBMED
Publication
BCMA Antigen Loss Through Acquired TNFRSF17 Deletion in Multiple Myeloma.
7 Oct 2026· International journal of laboratory hematology· PUBMED
Publication
Approval-standardized postmarketing safety reporting phenotypes of talquetamab versus BCMA-directed bispecific antibodies in multiple myeloma.
7 Oct 2026· Leukemia research· PUBMED
Publication
Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.
6 Oct 2026· Nature medicine· PUBMED
Trial
Immunoprofiling of the Patient Tumor Microenvironment in BCMA Targeted Therapies
1 Oct 2026· NA · NOT_YET_RECRUITING· CTGOV
Trial
A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma
1 Oct 2026· PHASE1 · NOT_YET_RECRUITING· CTGOV
Trial
CM336-SOC for Dynamically High-Risk Multiple Myeloma Study
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
F182112 in Combination With Isatuximab and Lenalidomide for the Treatment of Patients With Newly Diagnosed Multiple Myeloma
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV
Trial
Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma
1 Oct 2026· PHASE2 · NOT_YET_RECRUITING· CTGOV

Who works on it

Researchers who published on this target. Leave out your own co-author circle to find people you do not know yet.

No published researcher profile on this target yet.

We look for a fixed list of target names in titles, keywords, intervention names and MeSH terms. A mention does not prove that the work is aimed at that target.

Report an error